Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Theolytics has raised €5.5M across 2 funding rounds from 3 investors, most recently a Series A round in Jul 2021. Based in Oxford, UK; founded 2017; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2021-07-15 | Series A | — | M Ventures | View deal → |
| 2021-01-07 | Series A | €5.5M | Epidarex Capital,Taiho Ventures | View deal → |
